- Home
- BEAM vs KAR Comparison
BEAM vs KAR Comparison
Compare BEAM & KAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- KAR
- Stock Information
- Founded
- BEAM 2017
- KAR 2006
- Country
- BEAM United States
- KAR United States
- Employees
- BEAM N/A
- KAR N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- KAR Retail-Auto Dealers and Gas Stations
- Sector
- BEAM Health Care
- KAR Consumer Discretionary
- Exchange
- BEAM Nasdaq
- KAR Nasdaq
- Market Cap
- BEAM 1.8B
- KAR 2.1B
- IPO Year
- BEAM 2020
- KAR 2009
- Fundamental
- Price
- BEAM $16.19
- KAR $22.82
- Analyst Decision
- BEAM Strong Buy
- KAR Buy
- Analyst Count
- BEAM 11
- KAR 3
- Target Price
- BEAM $48.90
- KAR $23.67
- AVG Volume (30 Days)
- BEAM 1.9M
- KAR 866.4K
- Earning Date
- BEAM 05-06-2025
- KAR 05-07-2025
- Dividend Yield
- BEAM N/A
- KAR N/A
- EPS Growth
- BEAM N/A
- KAR N/A
- EPS
- BEAM N/A
- KAR 0.58
- Revenue
- BEAM $63,578,000.00
- KAR $1,818,700,000.00
- Revenue This Year
- BEAM N/A
- KAR $2.21
- Revenue Next Year
- BEAM $10.59
- KAR $6.84
- P/E Ratio
- BEAM N/A
- KAR $39.34
- Revenue Growth
- BEAM N/A
- KAR 6.67
- 52 Week Low
- BEAM $13.53
- KAR $15.44
- 52 Week High
- BEAM $35.25
- KAR $23.00
- Technical
- Relative Strength Index (RSI)
- BEAM 39.35
- KAR 69.89
- Support Level
- BEAM $15.35
- KAR $22.51
- Resistance Level
- BEAM $17.47
- KAR $23.00
- Average True Range (ATR)
- BEAM 0.90
- KAR 0.38
- MACD
- BEAM -0.07
- KAR 0.02
- Stochastic Oscillator
- BEAM 24.71
- KAR 84.48
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About KAR OPENLANE Inc.
Openlane Inc offers a digital marketplace for used vehicles. The services comprise financing, repossessions, repairs, transportation, warranty, and inventory services. It operates used-vehicle auctions and offers complete online services for all parties involved. The company has two operating segments which include Marketplace and Finance, of which it generates the majority of the revenue from the Marketplace segment.